Original Publication Date: 1 August, 2014
Publication / Source: Immunotherapy
Authors: Sandip P Patel, Takuya Osada, H Kim Lyerly, Michael A Morse
Achieving long-term control of colorectal cancers with therapeutic vaccines that generate potent anti-tumor T cell and antibody responses has been a goal for more than two decades. To date, clinical trials of these vaccines have demonstrated induction of immune responses, but clinical benefit has been limited. Improved vector delivery systems with enhanced immunostimulatory properties, decreased immunogenicity against vector and improved antigen presentation are some of the key features of modern tumor vaccines.